JP2016506939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506939A5 JP2016506939A5 JP2015555608A JP2015555608A JP2016506939A5 JP 2016506939 A5 JP2016506939 A5 JP 2016506939A5 JP 2015555608 A JP2015555608 A JP 2015555608A JP 2015555608 A JP2015555608 A JP 2015555608A JP 2016506939 A5 JP2016506939 A5 JP 2016506939A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- methyl
- phen
- phenylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 230000007135 neurotoxicity Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010012218 Delirium Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 206010059491 Intracranial haematoma Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000022077 chronic encephalitis Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- -1 methoxy-ethyl Chemical group 0.000 claims 66
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 208000012661 Dyskinesia Diseases 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 230000033001 locomotion Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 claims 1
- AFFPZJFLSDVZBV-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C(F)(F)F AFFPZJFLSDVZBV-UHFFFAOYSA-N 0.000 claims 1
- OJYLXZSHZGXVBZ-UHFFFAOYSA-N 2-anilino-3,3-difluoro-N-methyl-2-phenylpropanehydrazide Chemical compound FC(C(C(=O)N(N)C)(NC1=CC=CC=C1)C1=CC=CC=C1)F OJYLXZSHZGXVBZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000009017 Athetosis Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012225 Delirium tremens Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 206010071390 Resting tremor Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- VLFDIUYGPMHLQA-UHFFFAOYSA-N anilinomethanesulfonamide Chemical compound C1(=CC=CC=C1)NCS(=O)(=O)N VLFDIUYGPMHLQA-UHFFFAOYSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004799 bromophenyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 230000009206 glutamatergic signaling Effects 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims 1
- 125000001288 lysyl group Chemical group 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XGEGHDBEHXKFPX-NJFSPNSNSA-N methylurea Chemical compound [14CH3]NC(N)=O XGEGHDBEHXKFPX-NJFSPNSNSA-N 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000004963 pathophysiological condition Effects 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004344 phenylpropyl group Chemical group 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 230000001144 postural effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361760367P | 2013-02-04 | 2013-02-04 | |
| US61/760,367 | 2013-02-04 | ||
| PCT/EP2014/000169 WO2014117920A1 (en) | 2013-02-04 | 2014-01-23 | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506939A JP2016506939A (ja) | 2016-03-07 |
| JP2016506939A5 true JP2016506939A5 (enExample) | 2018-04-19 |
| JP6402115B2 JP6402115B2 (ja) | 2018-10-10 |
Family
ID=50000953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555608A Expired - Fee Related JP6402115B2 (ja) | 2013-02-04 | 2014-01-23 | 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9708321B2 (enExample) |
| EP (1) | EP2951179B1 (enExample) |
| JP (1) | JP6402115B2 (enExample) |
| CN (1) | CN104955826B (enExample) |
| AU (1) | AU2014211728B2 (enExample) |
| CA (1) | CA2899957A1 (enExample) |
| ES (1) | ES2796858T3 (enExample) |
| WO (1) | WO2014117920A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016078771A1 (en) * | 2014-11-21 | 2016-05-26 | Laboratorios Del Dr. Esteve, S.A. | 1,9-diazaspiro undecane compounds having multimodal activity against pain |
| KR20180019234A (ko) | 2015-06-26 | 2018-02-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체 |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| CN108699013B (zh) | 2016-09-08 | 2022-05-06 | 嘉泉大学校校产学协力团 | 螺醌衍生物、其制备方法及含有其作为活性成分的用于预防或治疗神经疾患的药物组合物 |
| CA3102326A1 (en) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| WO2020108619A1 (zh) * | 2018-11-30 | 2020-06-04 | 上海迪诺医药科技有限公司 | Mnk抑制剂 |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| CN116157404B (zh) | 2020-08-14 | 2025-10-14 | 诺华股份有限公司 | 杂芳基取代的螺哌啶基衍生物及其药物用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714093A (en) * | 1970-05-19 | 1973-01-30 | American Home Prod | Spiro [heterocycloalkyl-2'(1'h)-quinazoline]-4'(3'h)-ones |
| JPS4867287A (enExample) * | 1971-12-20 | 1973-09-13 | ||
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US5206240A (en) * | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| AU2003263323A1 (en) * | 2002-09-07 | 2004-03-29 | Celltech R And D Limited | Quinazolinone derivatives |
| US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| DE10250708A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4710606B2 (ja) | 2003-04-18 | 2011-06-29 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
| JPWO2008102749A1 (ja) | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| US20100144756A1 (en) | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| EP2311840A1 (en) | 2009-10-13 | 2011-04-20 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| WO2010008521A1 (en) | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| AU2009307825A1 (en) * | 2008-10-22 | 2010-04-29 | Rick FRIEDMAN | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011047481A1 (en) | 2009-10-23 | 2011-04-28 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| MX2012009378A (es) | 2010-02-11 | 2012-09-12 | Univ Vanderbilt | Compuestos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno y pirazolotiazol como potenciadores alostericos mglur4, composiciones y metodos para tratar disfunciones neurologicas. |
| WO2011143444A2 (en) | 2010-05-14 | 2011-11-17 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
| ITMI20122221A1 (it) * | 2012-12-21 | 2014-06-22 | C4T S C A R L | Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende |
-
2014
- 2014-01-23 CA CA2899957A patent/CA2899957A1/en not_active Abandoned
- 2014-01-23 AU AU2014211728A patent/AU2014211728B2/en not_active Ceased
- 2014-01-23 EP EP14701145.6A patent/EP2951179B1/en active Active
- 2014-01-23 WO PCT/EP2014/000169 patent/WO2014117920A1/en not_active Ceased
- 2014-01-23 ES ES14701145T patent/ES2796858T3/es active Active
- 2014-01-23 CN CN201480007416.4A patent/CN104955826B/zh not_active Expired - Fee Related
- 2014-01-23 US US14/765,615 patent/US9708321B2/en not_active Expired - Fee Related
- 2014-01-23 JP JP2015555608A patent/JP6402115B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531020A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| JP2018502891A5 (enExample) | ||
| JP2014528485A5 (enExample) | ||
| JP2014526549A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2013512926A5 (enExample) | ||
| JP2014515008A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2017512794A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2013544277A5 (enExample) | ||
| JP2021519263A5 (enExample) | ||
| JP2018514544A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2016506387A5 (enExample) | ||
| JP2013502423A5 (enExample) | ||
| JP2016517878A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| JP2017530199A5 (enExample) | ||
| JP2019525939A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). |